drugset / Trial / NCT05159388
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors
Phase 1/2
Terminated
46 enrolled
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors.
Timeline
- Start
- 2021-09-08
- Primary completion
- 2025-04-01
- Completion
- 2025-04-01
Publications
- Background Jungels C, Kotecki N, Calvo E, Garralda E, Price T, Zahn X, Abbas A, Mahnke L, Rauschning W, Morales-Kastresana A, Lucia Pattarini L, Bossenmaier B, Scholer-Dahirel A, Demuth T, Legrande J. Abstract CT255: Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors. Canc Res. 2022 Jun 15;82(12_Supplement):CT255. doi: https://doi.org/10.1158/1538-7445.AM2022-CT255
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRS-344/S095012 | Unknown | — | — |
| Background | Obinutuzumab | Monoclonal antibody | — | — |